Videos
Myeloma University: Monoclonal Antibodies
Learn about monoclonal antibodies as treatment for multiple myeloma
Description:
Learn how monoclonal antibodies can help a myeloma patient’s immune system to recognize and destroy cancer cells.
Module…
Videos
Myeloma University: the Patient Journey and CAR T-cell Therapy
CAR-T therapy management in multiple myeloma
Description:
A discussion of the patient journey and CAR-T therapy management in multiple myeloma.
Module Objectives:
- Learn…
Videos
Myeloma University: Renal Impairment
Learn about renal (kidney) impairment in multiple myeloma patients
Description:
Learn about renal (kidney) impairment in patients with multiple myeloma.
Module Objectives:
- Review important concepts…
News Article
HMP Global (a leading omnichannel healthcare events and education company) recently announced that the International Myeloma Foundation (IMF) is a partner for the 2023 Lymphoma, Leukemia & Myeloma Congress (LL&M)—the premier forum for industry-leading hematologic research and clinical case…
IMF Person
Cecilia Romero , Program & Technology Manager
Public Health Advocate | Technology Educator | Project Management Expert
Cecilia has more than 10 years of experience in project management and is passionate about keeping projects, programs and initiatives running…
IMF Person
Brittnay Brandon joins the IMF after 12 years of hospitality in hotels where she was involved in the planning and execution of many events from small medical meetings to large scale social galas. She has a background in planning many social events outside of the hotels including weddings,…
News Article
LOS ANGELES, July 13, 2023 — The International Myeloma Foundation (IMF) today announced that a 2023 IMF Patient and Family Seminar (PFS) will take place in-person from August 18-19 at the Sofitel Los Angeles at Beverly Hills on 8555 Beverly Blvd., Los Angeles, CA 90048…
Page
New data on multiple myeloma in Hispanics from ASH 2022 In this video filmed from the 64th American Society of Hematology (ASH) Annual Meeting and Exposition, Dr. Kara Cicero presents a study on the…
Videos
Comparing the Safety and Efficacy of Belamaf to Pd in RRMM
Evaluating the phase 3, open-label, randomized DREAMM-3 study
Dr. Katja Weisel presented a study evaluating the efficacy and safety of single-agent belantamab mafodotin (belamaf) (a first-in-class antibody drug conjugate)…
Videos
CARTITUDE-1: The Final Results
Ciltacabtagene Autoleucel's effects in heavily pretreated relapsed or refractory multiple myeloma
Dr. Nikhil Munshi discussed the results of a phase 1b/2 study of cilta-cel, a BCMA-targeting CAR-T therapy, in heavily pretreated patients with relapsed/…
News Article
A Comprehensive Online Educational Program on Multiple Myeloma
LOS ANGELES, July 06, 2023 -- The International Myeloma Foundation’s (IMF) Nurse Leadership Board (NLB) today announced the launch of Myeloma University—a FREE online educational program specially designed for…
Videos
Phase 2 MonumenTAL-1 Results of Talquetamab
The GPRC5DxCD3 bispecific antibody's role in relapsed refractory multiple myeloma
Dr. Carolina Schinke presented results on the updated findings of talquetamab in patients with relapsed or refractory multiple myeloma. Talquetamab is an off…
Videos
Quadruplet Induction Therapy, ASCT and MRD-modulated Consolidation and Treatment CessationMASTER trial analysis in newly diagnosed multiple myeloma Dr. Luciano Costa presented the final analysis of the MASTER trial at the European Hematology Association meeting in June 2023. The trial focused…
Videos
Carfilzomib, Pomalidomide, and Dex (KPd) in High-Risk Myeloma Patients
Results of maintenance therapy on high-risk myeloma
Dr. Ajay Nooka presented the results of a study on maintenance therapy for high-risk myeloma patients at ASCO 2023. The study focused on the combination…
Videos
Results from the Phase I, Open-Ended Study on BCMA/CD19 Dual-targeting Fast CAR-T GC012F
CAR-T therapy study in patients with relapsed and refractory multiple myeloma
Dr. Juan Du describes the results of the first open-label study of BCMA- and CD19-targeting CAR-T therapy…
Videos
Elranatamab in Refractory Multiple Myeloma with Prior BCMA Therapies
Evaluating the safety and efficacy of elranatamab
Dr. Ajay Nooka presents the efficacy and safety analysis of a drug called elranatamab in patients with refractory multiple myeloma who had prior exposure to…
Videos
Care Partners (Caregivers) Made Simple
Myeloma Made Simple: What Is a Care Partner?
Discover the vital role of care partners (or caregivers) in supporting individuals with multiple myeloma in the latest episode of 'Myeloma Made Simple.' Dr. Joseph Mikhael is joined by IMF VP of Support, Robin…
Videos
CARTITUDE-4 in Relapsed Multiple Myeloma
Results of the CARTITUDE-4 phase 3 clinical trial
Dr. Binod Dhakal presents the results of the CARTITUDE-4 phase 3 clinical trial were presented, evaluating the efficacy of cilta-cel, a BCMA-directed CAR-T cell therapy, compared to standard…
Videos
Durability of Responses with Biweekly Dosing of Teclistamab
Studying teclistamab dosing in patients with relapsed myeloma
The study presented by Dr. Saad Usmani focuses on the durability of response with bi-weekly dosing of teclistamab in patients with relapse refractory…
Videos
Ide-cel vs. Standard Regimens in Refractory Multiple Myeloma
Patient-Reported Outcomes of the KarMMa-3 Trial
Dr. Michel Delforge discusses the results of the "Patient-Reported Outcomes in Triple Class-Exposed Relapsed Refractory Multiple Myeloma Patients in the KarMMa-3 Trial"…
Videos
The IMF Brings Support Group Leaders to the American Society of Hematology (ASH) Meeting
Each year the International Myeloma Foundation brings support group leaders from across the nation to attend the annual American Society of Hematology (ASH) meeting. Together, they learn about the latest…
Videos
DREAMM-9 Study for Newly Diagnosed Multiple Myeloma
Evaluating Belantamab mafodotin with VRd or Rd
Dr. Saad Usmani presents the results of an ongoing Phase One randomized open-label study. The study aims to evaluate the safety and tolerability of Belantamab mafodotin (belamaf)…
Videos
Phase 1 Study Outcomes of CAR T-Cell Therapy for Relapsed Multiple Myeloma
Exploring additional targets for CAR T-cell therapy
Dr. Susan Bal presents the interim results of a phase one multi-center, open-label study evaluating the clinical activity of BMS 986393, a GPRC5D-directed…
Videos
KARMMA-3 Analysis: IDE-CEL vs Standard Regimens for High-Risk Myeloma
Analyzing the use of ide-cel in high-risk multiple myeloma patients
Dr. Krina Patel discusses the findings of the KarMMa-3 study, which focused on comparing the effectiveness of Idecabtagene vicleucel (ide-cel) versus…
Videos
RedirecTT-1 Study: Dual Targeting of Relapsed Myeloma with Teclistamab and Talquetamab
Exploring the results of the RedirecTT-1 study
Dr. Yael Cohen, presents the results of the RedirectT-1 study, which combines the use of two bispecific antibodies, Teclistamab (TEC) and Talquetamab (TAL…
Audio
An Interview with Oncology Social Worker Rebecca Zeiter
{"preview_thumbnail":"/sites/default/files/styles/video_embed_wysiwyg_preview/public/video_thumbnails/1KzFYPXD0YQ.jpg?itok=WLQkX7rZ","video_url":"https://youtu.be/1KzFYPXD0YQ","settings":{"responsive":1,"width":"854","height":"480…
News Article
Bipartisan legislation will bring equality to insurance coverage of life-saving medicines
WASHINGTON, D.C., June 15, 2023 -- The Coalition to Improve Access to Cancer Care (CIACC) and its members from across the cancer patient and provider…
Videos
Diane Hunter Was Diagnosed with Multiple Myeloma in 2017
She first heard about multiple myeloma from the doctor who diagnosed her while she was in the hospital's emergency department. The doctor arrived late at night and expressed his commitment to helping her get well. Diane shared her struggle…
Videos
Download Slides
At the IMWG Conference Series, “Making Sense of Treatment,” leading myeloma experts discussed the latest drug therapy news from the…
IMF Person
Becky Bosley, BSN, RN - Senior Director, Support Groups | Mid-AtlanticOncology Nurse Since 2006 | Breast & Ovarian Cancer Survivor | Support Group Leader Becky has been an oncology nurse since 2006, and for the last eight years, has primarily focused on…
Videos
LINKER-MM1 Trial for Relapsed Multiple Myeloma
Studying the optimal dose of Linvoseltamab in myeloma patients
LINKER-MM1 study presented the efficacy and safety of linvoseltamab, a BCMA bi-specific antibody, in patients with relapsed or refractory…
Videos
Global Drug Toxicity Trends
A study of adverse drug effects during myeloma treatment
A study conducted by Shahzad Raza, Majid Jaberi-Douraki, and colleagues analyzed the adverse effects of drugs used in the treatment of multiple myeloma, a type of cancer. The study examined data from the FDA…
Videos
MagnetisMM-3 Study on Relapsed Multiple Myeloma
Studying elranatamab in patients with relapsed or refractory myeloma
The MagnetisMM-3 study (NCT04649359) evaluated the efficacy and safety of elranatamab monotherapy in patients with relapsed or refractory multiple myeloma (RRMM). The study…
News Article
LOS ANGELES, JUNE 1, 2023—The International Myeloma Foundation (IMF) is proud to announce the recipients of this year’s Robert A. Kyle Achievement Award and Brian G.M. Durie Outstanding Achievement Award. The in-person awards ceremony will be held on June 8, Thursday at the 14th…
Videos
Shared Decision Making Made Simple
Myeloma Made Simple: What is shared decision making?
Join Dr. Joseph Mikhael and special guests Michael Tuohy, a 23-year myeloma survivor, and Robin Tuohy, IMF VP of Support, in the latest episode of 'Myeloma Made Simple.' Discover the power of…
Audio
An Interview with Myeloma Care Partner Jill Schock
Her journey as a myeloma care partner, navigating challenges and embracing life's twists.
In this episode of the 'A Day in the Life' podcast, Jill Schock shares her journey as a myeloma care partner, navigating the challenges of…
News Article
Myeloma ACTION Team Needs YOU!
Make a positive impact advocating for yourself and your loved ones
By Danielle Doheny, IMF Director, Public Policy & Advocacy
My father was diagnosed with myeloma in 2012. It is hard to describe the impact that his diagnosis…
News Article
International Myeloma Foundation (IMF) Patient, President & CEO Yelak Biru was recently featured in Innovation & Tech Today as a guest author, co-authoring “…
News Article
LOS ANGELES, May 25, 2023 — Founded in 2013 by the International Myeloma Foundation (IMF), the Global Myeloma Action Network® (GMAN®) will hold its Annual Summit in Frankfurt, Germany from June 2-4, 2023.
Over 30 advocacy leaders of myeloma patient…
News Article
The IMF Returns to In-Person Patient and Family Seminars in Boca Raton
The IMF Friends old and new celebrate reconnecting face-to-face after three years of online educational meetings
By Dr. Brian G.M. Durie, IMF Chairman & Chief Scientific Officer
In…
News Article
Fostering greater diversity in doctors working in myeloma
A novel mentorship initiative for African American medical students
By Dr. Joseph Mikhael, IMF Chief Medical Officer
Myeloma may well be the cancer with the greatest disparity in the African American community…
News Article
LOS ANGELES, CA, MAY 18, 2023 — Diagnosed in 2008 at age 59 with multiple myeloma, Andy Sninsky continues to be a formidable inertia in motion and a perpetual source of inspiration for the International Myeloma Foundation (IMF) and the myeloma community at large.…
News Article
Now on its 15th year, the Annual Czerkies Memorial Golf Outing continues to honor the memory of Edward and Carolyn Czerkies by raising funds for the International Myeloma Foundation (IMF).
This year, the annual event will take place on Saturday, June 3 at Bolingbrook Golf Club in…